CSI Market
Sign In | Register

Beta Bionics Inc (BBNX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access BBNX Annual Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Beta Bionics Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-45.30
Depreciation & amortization1.29
Amortization of Other Assets0.18
Increase (Decrease) in Deferred Revenue0.48
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.02
Increase (Decrease) in Inventories2.02
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation14.32
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Provision For Excess And Obsolete Inventory-0.20
Accretion Of Discount On Short- Term Investments-
Operating Lease Right Of Use Asset Amortization Expense0.40
Increase Decrease In Funded Research And Development Liability-
Increase Decrease In Operating Lease Liability-0.39
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.95
Increase (Decrease) in Accounts Payable-0.47
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-5.44
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.37
Other Working Capital0.04
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-5.19
Discontinued operations0.00
Net Cash flow from Operating Activities-38.45
Investing Activities
Capital Expenditures-2.42
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Short-term Investments96.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Long-term Investments-44.81
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities48.77
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.42
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Non Cash Unrealized Gain Loss On Short Term Investments-
Warrants Issued In Connection With Convertible Preferred Stock-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities2.42
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-40.87
Total Cash Flow12.74
4 historic quarters locked

Sign in to unlock the full Beta Bionics Inc cash flow history.

Sign In Create Free Account

About Beta Bionics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-323777

Figures are derived from filed reports and may be restated. Historical data is subject to revision.